Haisheng Medical Completes First Industrial and Commercial Change After Listing, Registered Capital Increased to 75.2941 Million Yuan

MaticHoleFiller · 2026-03-17T04:20:26+00:00

Zhejiang Haisheng Medical Devices Co., Ltd. completed its initial business registration information change, with registered capital increased from 64 million yuan to 75.2941 million yuan, and officially changed to "Co., Ltd. (Listed)". The company's articles of association have been revised to strengthen share lock-up and connected transaction supervision clauses for controlling shareholders and actual controllers, in order to standardize governance structure and protect investor rights.

MaticHoleFiller

2026-03-17 04:20:26

Abstract generation in progress

[Beijing, March 12, 2026] Zhejiang Haisheng Medical Equipment Co., Ltd. (Stock Code: 920166, Stock Name: Haisheng Medical) announced today that the company has completed its first post-listing business registration change. The registered capital has increased from 64 million yuan to 75,294,118 yuan, and the company type has officially changed to “Joint Stock Limited Company (Listed).” At the same time, the company plans to amend relevant clauses of the Articles of Association to meet the requirements of listed company governance.

The announcement shows that Haisheng Medical successfully listed on the Beijing Stock Exchange on February 12, 2026. The company issued 11,294,118 shares to qualified investors, resulting in the total share capital increasing from 64 million shares to 75,294,118 shares, with the registered capital adjusted accordingly to 75,294,118 yuan.

Main revision highlights:

Original Provision	Revised Provision
Article 3 The company was approved by the Beijing Stock Exchange on 【】【】【】】 and approved by the China Securities Regulatory Commission on 【】【】【】】 to issue 【】 ordinary shares to qualified investors, and listed on the Beijing Stock Exchange on 【】【】【】】.	Article 3 The company was approved by the Beijing Stock Exchange on November 7, 2025, approved by the China Securities Regulatory Commission on December 31, 2025, to issue 11,294,118 RMB ordinary shares, and listed on the Beijing Stock Exchange on February 12, 2026.
Article 6 The company’s registered capital is 【】 ten thousand yuan.	Article 6 The company’s registered capital is 75,294,118 yuan.
Article 20 The total number of shares issued by the company is 【】 million shares, all of which are RMB ordinary shares, with a par value of 1 yuan per share, and no other classes of shares.	Article 20 The total number of shares issued by the company is 75,294,118 shares, all of which are RMB ordinary shares, with a par value of 1 yuan per share, and no other classes of shares.
Article 29 Before the company’s public issuance of shares, the shares already issued shall not be transferred within one year from the date of listing and trading of the company’s stock on the stock exchange. Directors and senior management shall report their holdings and changes in the company’s shares. During their tenure, the transfer of shares shall not exceed 25% of their total holdings. Shares held by them cannot be transferred within one year from the date of listing and trading. After resignation, they shall not transfer their shares within six months. If the shares are pledged within the legal and regulatory transfer restriction period, the pledgee shall not exercise the pledge during the restriction period.	Article 29 The company’s controlling shareholders, actual controllers, and their relatives, as well as shareholders holding or controlling more than 10% of voting rights before listing, or entities that can actually control more than 10% of voting rights without direct ownership, shall not transfer or entrust others to manage their shares within 12 months after the company’s shares are publicly issued and listed. “Relatives” refer to spouses, children and their spouses, parents and their spouses, siblings and their spouses, spouses’ siblings, parents of children, and other close family members. Directors and senior management shall report their shareholdings and changes. During their tenure, the transfer of shares shall not exceed 25% of their total holdings. Shares cannot be transferred within one year from the listing date. After resignation, they shall not transfer their shares within six months. Pledged shares within the legal and regulatory transfer restriction period shall not be exercised by the pledgee during the restriction period.
Article 40 If shareholders abuse their rights to cause losses to the company or other shareholders, they shall bear compensation liability according to law. Shareholders abusing the company’s independent legal personality and limited liability to evade debts and severely harm creditors’ interests shall be jointly liable for the company’s debts.	Article 40 The company’s controlling shareholders, actual controllers, directors, supervisors, and senior management shall not use related-party relationships to damage the company’s interests. If violations cause losses to the company, they shall bear compensation liability. Controlling shareholders and actual controllers owe a duty of good faith to the company and its public shareholders. They shall exercise their rights as investors strictly according to law and shall not use profit distribution, asset restructuring, external investments, capital occupation, or guarantees to harm the legitimate rights and interests of the company and public shareholders, nor damage the company’s and shareholders’ interests through their controlling position.

The revision of the Articles of Association emphasizes strengthening the share lock-up requirements for controlling shareholders, actual controllers, and their relatives, clarifies the lock-up period for shareholders holding more than 10% before listing, and refines the regulation of related-party transactions. The company emphasizes that, aside from these revisions, other provisions of the original Articles of Association remain unchanged.

The announcement also states that the change in registered capital and the revision of the Articles of Association are subject to approval by the company’s shareholders’ meeting and registration with the administrative department. The company’s registered address remains unchanged.

Haisheng Medical states that this business registration change and Articles of Association revision are important measures to improve corporate governance after listing, which will help further standardize company operations, protect investors—especially small and medium investors—and lay a solid foundation for the company’s sustainable and healthy development.

Click to view the original announcement>>

Disclaimer: Market risks exist; investments should be cautious. This article is automatically published by an AI model based on third-party databases and does not represent Sina Finance’s views. Any information in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for accuracy. If you have questions, contact biz@staff.sina.com.cn.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.